{"id":"drug-prc-063","safety":{"commonSideEffects":[{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Increased heart rate"},{"rate":null,"effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PRC-063 uses a proprietary extended-release technology to deliver methylphenidate over an extended period, allowing for once-daily dosing. By inhibiting the reuptake of dopamine and norepinephrine in the central nervous system, it enhances neurotransmitter availability to improve attention, focus, and impulse control in patients with ADHD.","oneSentence":"PRC-063 is an extended-release formulation of methylphenidate designed to provide sustained dopamine and norepinephrine reuptake inhibition for ADHD symptom management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:04.994Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"}]},"trialDetails":[{"nctId":"NCT02168127","phase":"PHASE3","title":"Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2014-05","conditions":"ADHD","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Methylphenidate"],"phase":"phase_3","status":"active","brandName":"Drug: PRC-063","genericName":"Drug: PRC-063","companyName":"Rhodes Pharmaceuticals, L.P.","companyId":"rhodes-pharmaceuticals-l-p","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PRC-063 is an extended-release formulation of methylphenidate designed to provide sustained dopamine and norepinephrine reuptake inhibition for ADHD symptom management. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}